Malignant glioma
Information
- Disease name
- Malignant glioma
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03678883 | Active, not recruiting | Phase 2 | 9-ING-41 in Patients With Advanced Cancers | January 4, 2019 | November 2025 |
| NCT01817751 | Active, not recruiting | Phase 2 | Sorafenib, Valproic Acid, and Sildenafil in Treating Patients With Recurrent High-Grade Glioma | April 11, 2013 | October 30, 2027 |
| NCT03220035 | Active, not recruiting | Phase 2 | Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) | November 8, 2017 | September 22, 2024 |
| NCT04160494 | Active, not recruiting | Phase 1 | D2C7-IT With Atezolizumab for Recurrent Gliomas | February 25, 2020 | December 2027 |
| NCT03213678 | Active, not recruiting | Phase 2 | Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) | November 28, 2017 | October 1, 2024 |
| NCT01991977 | Active, not recruiting | Phase 2 | 18F-DOPA-PET in Finding Tumors in Patients With Newly Diagnosed Gliomas Undergoing Radiation Therapy | December 2013 | December 14, 2024 |
| NCT02020720 | Active, not recruiting | Early Phase 1 | 18F-DOPA-PET in Planning Surgery in Patients With Gliomas | January 22, 2014 | December 15, 2024 |
| NCT03299309 | Active, not recruiting | Phase 1 | PEP-CMV in Recurrent MEdulloblastoma/Malignant Glioma | June 29, 2018 | April 2025 |
| NCT02986178 | Active, not recruiting | Phase 2 | PVSRIPO in Recurrent Malignant Glioma | June 1, 2017 | March 2024 |
| NCT02549833 | Active, not recruiting | Phase 1 | Neo-adjuvant Evaluation of Glioma Lysate Vaccines in WHO Grade II Glioma | October 17, 2016 | August 31, 2024 |
| NCT02323880 | Active, not recruiting | Phase 1 | Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas | October 30, 2015 | September 22, 2024 |
| NCT02104310 | Active, not recruiting | A Pilot Study Using 18F-DOPA PET-guided Radiotherapy in Gliomas | April 2014 | March 2031 | |
| NCT03244995 | Active, not recruiting | N/A | Mind-Body Intervention in Glioma Couples | August 6, 2017 | October 31, 2024 |
| NCT03581292 | Active, not recruiting | Phase 2 | Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations | November 6, 2018 | September 22, 2024 |
| NCT03389230 | Active, not recruiting | Phase 1 | Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma | August 14, 2018 | June 14, 2024 |
| NCT03233204 | Active, not recruiting | Phase 2 | Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) | September 14, 2017 | September 22, 2024 |
| NCT04175301 | Active, not recruiting | Phase 2 | Effect H2 Water on QoL of Patients Receiving Radiotherapy for High Grade Gliomas. | October 31, 2019 | August 31, 2025 |
| NCT03893903 | Active, not recruiting | Phase 1 | AMPLIFYing NEOepitope-specific VACcine Responses in Progressive Diffuse Glioma | October 19, 2018 | December 2024 |
| NCT04197492 | Active, not recruiting | Phase 2 | Hypofractionated Stereotactic Radiotherapy With Anlotinib in Patients With Recurrent High-Grade Gliomas | December 16, 2019 | December 31, 2024 |
| NCT03334305 | Active, not recruiting | Phase 1 | Adoptive Cellular Therapy in Pediatric Patients With High-grade Gliomas | May 16, 2018 | May 2028 |
| NCT00766753 | Completed | Phase 1/Phase 2 | Vaccination-Dendritic Cells With Peptides for Recurrent Malignant Gliomas | December 2006 | June 2016 |
| NCT00782756 | Completed | Phase 2 | Bevacizumab, Temozolomide and Hypofractionated Radiotherapy for Patients With Newly Diagnosed Malignant Glioma | October 28, 2008 | March 23, 2017 |
| NCT00859222 | Completed | Phase 1/Phase 2 | LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma | March 2009 | December 2015 |
| NCT00900757 | Completed | Phase 2 | Intravenous Palonosetron With Radiotherapy and Concomitant Temozolomide | August 2009 | December 2012 |
| NCT00919737 | Completed | Phase 1/Phase 2 | Study of NPC-08 is to Treat for Newly-Diagnosed Malignant Glioma and Recurrent Glioblastoma Multiforme | June 2009 | April 2011 |
| NCT00953121 | Completed | Phase 2 | Bevacizumab Plus Irinotecan Plus Carboplatin for Recurrent Malignant Glioma (MG) | September 2009 | January 2013 |
| NCT01004874 | Completed | Phase 2 | Avastin/Radiation (XRT)/Temozolomide (Temodar) Followed by Avastin/Temodar/Topotecan for Glioblastoma | December 30, 2009 | November 2, 2021 |
| NCT01017250 | Completed | N/A | Radiosurgery and Avastin for Recurrent Malignant Gliomas | December 2009 | February 2012 |
| NCT01167322 | Completed | Phase 3 | Study of NPC-07 for Fluorescence-guided Resection of Malignant Gliomas | August 2010 | December 2011 |
| NCT01266031 | Completed | Phase 1/Phase 2 | Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma | July 12, 2011 | January 31, 2017 |
| NCT01303835 | Completed | Phase 2 | Low Dose Naltrexone for Glioma Patients | May 2011 | May 2015 |
| NCT01316809 | Completed | Phase 1 | AZD8055 for Adults With Recurrent Gliomas | March 4, 2011 | April 4, 2016 |
| NCT01386580 | Completed | Phase 1/Phase 2 | An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma. | July 2011 | December 2014 |
| NCT01392209 | Completed | Phase 1 | Hypofractionated Stereotactic Radiotherapy With Bevacizumab in the Treatment of Recurrent Malignant Glioma | July 8, 2011 | November 15, 2019 |
| NCT01454596 | Completed | Phase 1/Phase 2 | CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII | May 16, 2012 | January 17, 2019 |
| NCT01491893 | Completed | Phase 1 | PVSRIPO for Recurrent Glioblastoma (GBM) | April 25, 2012 | October 1, 2021 |
| NCT01738646 | Completed | Phase 2 | Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients | January 2013 | February 2016 |
| NCT01740258 | Completed | Phase 2 | Bevacizumab Beyond Progression (BBP) | January 2013 | November 14, 2019 |
| NCT01792505 | Completed | Phase 1 | Dendritic Cell Vaccine With Imiquimod for Patients With Malignant Glioma | October 2009 | October 2016 |
| NCT01808820 | Completed | Phase 1 | Dendritic Cell (DC) Vaccine for Malignant Glioma and Glioblastoma | August 21, 2013 | July 16, 2022 |
| NCT01811992 | Completed | Phase 1 | Combined Cytotoxic and Immune-Stimulatory Therapy for Glioma | April 2014 | January 2021 |
| NCT01891747 | Completed | Phase 1 | A Phase I Study of High-dose L-methylfolate in Combination With Temozolomide and Bevacizumab in Recurrent High Grade Glioma | July 2013 | January 31, 2022 |
| NCT02023346 | Completed | Prognostic Awareness and Patient-Physician Communication in Malignant Glioma | December 2013 | October 30, 2018 | |
| NCT02186262 | Completed | Rotating Frame Relaxation and Diffusion Weighted Imaging of Human Gliomas | March 2014 | December 2017 | |
| NCT02278510 | Completed | Early Phase 1 | Topotecan Using Convection-Enhanced Delivery (CED) in High Grade Glioma | December 9, 2014 | November 10, 2015 |
| NCT02300506 | Completed | Post-Marketing Surveillance of Long-Term Observation of Gliadel Wafer-Investigation of Vital Prognosis in Patients With High Grade Glioma | January 10, 2014 | July 10, 2016 | |
| NCT02300532 | Completed | Post-Marketing Surveillance of Gliadel 7.7mg Implant (All-case Observational Study) | January 10, 2013 | March 24, 2015 | |
| NCT02303678 | Completed | Phase 1 | D2C7 for Adult Patients With Recurrent Malignant Glioma | May 5, 2015 | March 25, 2024 |
| NCT02311582 | Completed | Phase 1/Phase 2 | MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas | August 5, 2015 | April 15, 2024 |
| NCT02313272 | Completed | Phase 1 | Hypofractionated Stereotactic Irradiation (HFSRT) With Pembrolizumab and Bevacizumab for Recurrent High Grade Gliomas | July 28, 2015 | August 9, 2021 |
| NCT02315989 | Completed | N/A | Early-Phase Safety of Proton Therapy Equipment | August 2014 | February 2015 |
| NCT02861222 | Completed | Phase 1 | Myocet® in Children With Relapsed or Refractory Non-brainstem Malignant Glioma | October 2010 | April 2013 |
| NCT00024570 | Completed | Phase 1/Phase 2 | Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma | November 2000 | July 2007 |
| NCT00032903 | Completed | Phase 1/Phase 2 | This is an Early Study to Investigate the Effect of Gimatecan® in Adults With Malignant Glioma. | March 2002 | October 2005 |
| NCT00041587 | Completed | Phase 1/Phase 2 | Pre-operative IL13-PE38QQR in Patients With Recurrent or Progressive Malignant Glioma | July 2002 | July 2007 |
| NCT00064779 | Completed | Phase 1 | Imaging Study of the Distribution of IL13-PE38QQR Infused Before and After Surgery in Adult Patients With Recurrent Malignant Glioma | July 2003 | July 2007 |
| NCT00087451 | Completed | Phase 1 | Safety Study of AP23573 in Patients With Progressive or Recurrent Glioma (8669-023)(COMPLETED) | July 2004 | November 2005 |
| NCT00103038 | Completed | N/A | Ferumoxytol in Improving MR Imaging in Patients With High-Grade Brain Tumors or Cerebral Metastases | June 4, 2004 | June 10, 2016 |
| NCT00125697 | Completed | Characterization of Serial Magnetic Resonance Spectroscopy Imaging in Patients With Malignant Glioma Undergoing Radiotherapy | May 2005 | June 2015 | |
| NCT00125710 | Completed | Comparative 2-D Tumor Analysis in Familial Gliomas | June 1998 | ||
| NCT00157703 | Completed | Phase 1 | G207 Followed by Radiation Therapy in Malignant Glioma | May 2005 | December 2008 |
| NCT00190723 | Completed | Phase 2 | A Study of LY317615 in Patients With Brain Tumors | October 2002 | December 2006 |
| NCT00283556 | Completed | Phase 1/Phase 2 | High Dose Camptothecin-11 (CPT-11) in Recurrent Unresectable Malignant Glioma | August 2001 | December 2008 |
| NCT00458601 | Completed | Phase 2 | Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme | August 2007 | May 2016 |
| NCT00528684 | Completed | Phase 1 | Safety and Efficacy Study of REOLYSIN® in the Treatment of Recurrent Malignant Gliomas | July 2006 | June 2010 |
| NCT00576446 | Completed | Phase 1 | Surgical Resection With Gliadel Wafer Followed by Dendritic Cells Vaccination for Malignant Glioma Patients | April 2007 | May 2012 |
| NCT00589875 | Completed | Phase 2 | Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma | March 2007 | August 2016 |
| NCT00634231 | Completed | Phase 1 | A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors | October 2010 | June 2021 |
| NCT00717197 | Completed | Phase 2 | Study of Capecitabine to Treat Recurrent High Grade Gliomas | July 2008 | May 2013 |
| NCT00751270 | Completed | Phase 1 | Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant Gliomas | November 2005 | January 2011 |
| NCT00766467 | Completed | Phase 2 | A Randomized Placebo-Controlled Trial of Armodafinil (Nuvigil) for Fatigue in Patients With Malignant Gliomas | September 2008 | July 2014 |
| NCT02330562 | Completed | Phase 1/Phase 2 | Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab | April 15, 2015 | June 2, 2021 |
| NCT02457845 | Completed | Phase 1 | HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors | May 2016 | January 2024 |
| NCT02465268 | Completed | Phase 2 | Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme | August 9, 2016 | November 30, 2023 |
| NCT02507583 | Completed | Phase 1 | Antisense102: Pilot Immunotherapy for Newly Diagnosed Malignant Glioma | September 1, 2015 | August 17, 2020 |
| NCT02526017 | Completed | Phase 1 | Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers | September 8, 2015 | November 18, 2019 |
| NCT02529072 | Completed | Phase 1 | Nivolumab With DC Vaccines for Recurrent Brain Tumors | January 2016 | December 30, 2019 |
| NCT02540161 | Completed | Phase 2 | Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma | February 1, 2016 | April 27, 2020 |
| NCT02590263 | Completed | Phase 1/Phase 2 | Study Evaluating ABT-414 in Japanese Subjects With Malignant Glioma | August 24, 2015 | August 27, 2020 |
| NCT02644291 | Completed | Phase 1 | Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors | May 2016 | June 9, 2022 |
| NCT02661282 | Completed | Phase 1/Phase 2 | Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma | June 1, 2016 | February 23, 2022 |
| NCT02794883 | Completed | Phase 2 | Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma | November 1, 2016 | June 17, 2020 |
| NCT02829931 | Completed | Phase 1 | Hypofractionated Stereotactic Irradiation With Nivolumab, Ipilimumab and Bevacizumab in Patients With Recurrent High Grade Gliomas | August 22, 2016 | November 22, 2022 |
| NCT00024557 | Completed | Phase 1 | Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant Glioma Patients | June 2001 | July 2007 |
| NCT02892708 | Completed | Phase 3 | Impact of Surgery on the Treatment of Supratentorial Malignant Gliomas in Subjects Aged 70 and Over | April 2008 | April 2018 |
| NCT02903069 | Completed | Phase 1 | Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer | August 17, 2016 | January 25, 2021 |
| NCT03043391 | Completed | Phase 1 | Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children | November 7, 2017 | March 23, 2022 |
| NCT03387020 | Completed | Phase 1 | Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors | January 13, 2018 | April 1, 2020 |
| NCT03471546 | Completed | N/A | Early Palliative Care Intervention in Malignant Glioma | May 16, 2018 | June 17, 2019 |
| NCT03501134 | Completed | Quality of Life of Patients With Glioblastoma (GBM) Treated With Tumor-Treating Fields | August 8, 2018 | June 3, 2021 | |
| NCT03615404 | Completed | Phase 1 | Cytomegalovirus (CMV) RNA-Pulsed Dendritic Cells for Pediatric Patients and Young Adults With WHO Grade IV Glioma, Recurrent Malignant Glioma, or Recurrent Medulloblastoma | October 5, 2018 | July 2, 2020 |
| NCT03735498 | Completed | N/A | Psychological Intervention for Caregivers of Patients With Malignant Gliomas | February 8, 2019 | March 30, 2020 |
| NCT03778294 | Completed | Phase 2 | 18F-DOPA-PET/MRI Scan in Imaging Elderly Patients With Newly Diagnosed Grade IV Malignant Glioma or Glioblastoma During Planning for a Short Course of Proton Beam Radiation Therapy | March 28, 2019 | November 26, 2023 |
| NCT03915912 | Completed | N/A | Mindfulness Meditation in Glioma Patients | April 11, 2019 | January 9, 2020 |
| NCT04013828 | Completed | Treatment Decision-making in Patients With Recurrent High-grade Glioma | May 6, 2019 | April 8, 2022 | |
| NCT04109209 | Completed | N/A | Psychological Intervention For Brain Tumor Caregivers | October 9, 2019 | September 13, 2022 |
| NCT04630379 | Completed | N/A | Early Integration of Palliative Care Using the BEACON PROQOL in Patients With High Grade Glioma and Their Caregivers | June 13, 2018 | August 31, 2020 |
| NCT05486247 | Completed | Molecular Characterization of Gliomas Using a Broad Next Generation Sequencing (NGS)Panel | February 4, 2015 | May 1, 2022 | |
| NCT05773664 | Not yet recruiting | Phase 1 | Dexamethasone and Azeliragon for Management of Post-Resection Cerebral Edema in Patients With Glioblastoma | August 15, 2024 | November 29, 2024 |
| NCT04903795 | Not yet recruiting | Phase 1 | Bispecific T Cell Engager BRiTE for Patients With Grade IV Malignant Glioma | December 2026 | December 2026 |
| NCT03155620 | Recruiting | Phase 2 | Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) | July 31, 2017 | September 30, 2027 |
| NCT03033992 | Recruiting | N/A | Optune for Children With High-Grade Glioma or Ependymoma, and Optune With Radiation Therapy for Children With DIPG | April 4, 2017 | September 21, 2032 |
| NCT04817254 | Recruiting | Phase 2 | Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma | December 8, 2021 | December 31, 2026 |
| NCT03411408 | Recruiting | N/A | Accelerated Hypofractionated Intensity - Modulated Radiotherapy After Hyperbaric Oxygenation for Recurrent High Grade Glioma. | February 22, 2018 | May 2024 |
| NCT04937413 | Recruiting | Early Phase 1 | The PCSK9i Inhibitor Evolocumab - a Surgical Trial of Pharamcodynamics and Kinetics Evaluation | October 8, 2021 | June 2025 |
| NCT03510208 | Recruiting | Phase 1/Phase 2 | Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery | May 16, 2018 | December 31, 2024 |
| NCT05030298 | Recruiting | Phase 1/Phase 2 | Preoperative Radiosurgery for the Treatment of High Grade Glioma, The NeoGlioma Study | May 23, 2023 | September 15, 2025 |
| NCT03684109 | Recruiting | N/A | Non-invasive Glioma Characterization Through Molecular Imaging | January 25, 2019 | January 2025 |
| NCT03718767 | Recruiting | Phase 2 | Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype | March 27, 2019 | February 27, 2026 |
| NCT05045027 | Recruiting | Early Phase 1 | Simultaneous Multinuclear Metabolic MRI in Newly Diagnosed or Recurrent Glioma | September 1, 2021 | September 10, 2027 |
| NCT03746080 | Recruiting | Phase 2 | Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With Glioblastoma | December 4, 2018 | July 2027 |
| NCT03749187 | Recruiting | Phase 1 | BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas | April 3, 2019 | July 30, 2029 |
| NCT05099003 | Recruiting | Phase 1/Phase 2 | A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG) | May 31, 2022 | June 30, 2027 |
| NCT05293197 | Recruiting | Phase 1 | Safety Study of the Repeated Opening of the Blood-brain Barrier With the SonoCloud® Device to Treat Malignant Brain Tumors in Pediatric Patients | February 6, 2023 | October 2026 |
| NCT02359565 | Recruiting | Phase 1 | Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma | May 22, 2015 | December 31, 2026 |
| NCT03919071 | Recruiting | Phase 2 | Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma | February 20, 2020 | September 30, 2027 |
| NCT03952598 | Recruiting | N/A | Studying the Biology of IDH-mutant Gliomas Via Longitudinal Observation of 2-hydroxyglutarate (2-HG) Using MR Spectroscopy | October 16, 2019 | December 31, 2025 |
| NCT05660369 | Recruiting | Phase 1 | CARv3-TEAM-E T Cells in Glioblastoma | March 22, 2023 | June 1, 2026 |
| NCT04323046 | Recruiting | Phase 1 | Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults | October 2, 2020 | March 1, 2029 |
| NCT05717153 | Recruiting | Early Phase 1 | Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade Glioma | October 1, 2023 | September 15, 2027 |
| NCT04771806 | Recruiting | Serial Advanced Magnetic Resonance Imaging Scan for Guidance of Personalized Adaptive Radiotherapy for High Grade Glioma | April 1, 2019 | February 2, 2027 | |
| NCT02663271 | Terminated | Phase 2 | TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma | December 19, 2016 | June 11, 2021 |
| NCT02375334 | Terminated | Adherence Monitoring System in Managing Myelosuppression in Patients With Newly Diagnosed Malignant Gliomas Receiving Temozolomide and Radiation Therapy | February 2015 | January 2017 | |
| NCT02855086 | Terminated | Phase 1/Phase 2 | Cetuximab-IRDye 800CW in Detecting Tumors in Patients With Malignant Glioma Undergoing Surgery | October 2016 | November 22, 2016 |
| NCT02924038 | Terminated | Phase 1 | A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG) | April 3, 2017 | December 31, 2022 |
| NCT01515085 | Terminated | MRI-Guided Laser Induced Thermal Therapy | August 2011 | June 2012 | |
| NCT01432171 | Terminated | N/A | Lacosamide in Preventing Seizures in Participants With Malignant Glioma | July 25, 2012 | June 20, 2017 |
| NCT01400958 | Terminated | Phase 2 | Nuvigil or Placebo in Newly Diagnosed Malignant Glioma | December 2010 | September 2013 |
| NCT01351519 | Terminated | Phase 2 | A Study of Aminolevulinic Acid Used to Enhance Visualization and Surgical Removal of Brain Tumors | May 2011 | January 2015 |
| NCT01868906 | Terminated | Phase 2 | FMISO-PET in Brain Tumors and SCS Effect | June 2013 | September 17, 2017 |
| NCT04650204 | Terminated | Phase 4 | Perampanel for the Reduction of Seizure Frequency in Patients With High-grade Glioma and Focal Epilepsy | December 4, 2020 | April 30, 2023 |
| NCT02039778 | Terminated | N/A | Stem Cell Radiotherapy and Temozolomide for Newly Diagnosed High-grade Glioma | December 2013 | December 2015 |
| NCT00735436 | Terminated | Phase 2 | A Study of Gliadel Followed by Avastin + Irinotecan for Glioblastoma Multiforme (GBM) | December 2008 | October 2012 |
| NCT02659800 | Terminated | Phase 1 | Study of the Effect NT-I7 on CD4 Counts in Patients With High Grade Gliomas | October 30, 2018 | October 3, 2023 |
| NCT02764151 | Terminated | Phase 1 | First in Patient Study for PF-06840003 in Malignant Gliomas | September 9, 2016 | December 26, 2018 |
| NCT02025231 | Terminated | Phase 1/Phase 2 | Image Guided Reirradiation of High-grade Glioma | December 2011 | April 2015 |
| NCT02371031 | Terminated | Phase 1 | FDOPA-PET/MRI for the Pre-operative Evaluation of Gliomas | March 2015 | July 2016 |
| NCT01235845 | Unknown status | Phase 1/Phase 2 | Dendritic Cell (DC) Activated Cytokine-induced Killer Cell (DCIK) Combined With DC Treatment for Glioma | January 2011 | September 2013 |
| NCT02047058 | Unknown status | Treatment Response and Prognosis in Glioma Patients: Q Cell and Its Biological Characteristics | March 2014 | March 2017 | |
| NCT00114309 | Unknown status | Phase 2 | 131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma | November 2004 | August 2009 |
| NCT00075387 | Unknown status | Phase 2 | Combination Chemotherapy With or Without Sodium Thiosulfate in Preventing Low Platelet Count While Treating Patients With Malignant Brain Tumors | March 7, 2003 | April 30, 2024 |
| NCT02391246 | Unknown status | Radionecrosis and FDG PET | June 2015 | March 2020 | |
| NCT04943718 | Unknown status | Phase 1 | Personalized Vaccine for Patients With Recurrent Malignant Glioma | July 15, 2021 | June 13, 2024 |
| NCT00591058 | Unknown status | Phase 1 | Safety and Dose-Finding Study of TM-601 in Adults With Recurrent Malignant Glioma | February 2008 | February 2010 |
| NCT00683761 | Unknown status | Phase 1/Phase 2 | A Study of 131I-TM601 in Adults With Recurrent Malignant Glioma | August 2008 | April 2010 |
| NCT04521946 | Withdrawn | Phase 1 | Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer | January 14, 2021 | December 20, 2022 |
| NCT01952886 | Withdrawn | Phase 2 | Patient Satisfaction, Efficacy and Compliance of Antiemetic Patch vs Pill in Malignant Glioma Patients | ||
| NCT01249105 | Withdrawn | Phase 2 | MK-2206 for Recurrent Malignant Glioma | ||
| NCT03956706 | Withdrawn | N/A | Study of Stereotactic Radiosurgery to the Subventricular Zone in Malignant Gliomas | December 24, 2018 | September 1, 2022 |
| NCT03973879 | Withdrawn | Phase 1/Phase 2 | Combination of PVSRIPO and Atezolizumab for Adults With Recurrent Malignant Glioma | February 2020 | January 2024 |